

## Cancidas - (50, 70 mg/Vial; Powder, Intravenous)

<b>Generic Name</b>	Caspofungin Acetate	<b>Innovator</b>	Merck
<b>Dosage</b>	50, 70 mg/Vial; Powder, Intravenous	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	Less Than 5
<b>Final Approvals</b>	More Than 5	<b>Generic Launches</b>	Less Than 5
<b>Indication</b>	Used to treat a variety of serious fungal infections. It is often used in patients who cannot use or do not respond to other antifungal medications		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.